Introduction {#S1}
============

Gestational diabetes mellitus (GDM), a frequent disorder in pregnancy, is defined as any degree of glucose intolerance that first develops or is first recognized during pregnancy ([@B1], [@B2]). The incidence of GDM is rapidly increasing worldwide, and it affects 1--25% of all pregnancies depending on patient demographics, screening strategies, and diagnostic thresholds ([@B2], [@B3]). According to the Hyperglycemia and Adverse Pregnancy Outcome Study Cooperative, GDM increases the number of maternal and fetal complications ([@B4]--[@B6]).

It has been hypothesized that vitamin D deficiency is a risk factor associated with GDM. The need for vitamin D is higher during specific stages of life, including during the rapid growth of the fetus in the embryonic stage, infancy, the early stages of childhood, puberty, and pregnancy ([@B6]). In addition to its classical roles in influencing calcium absorption and bone metabolism, vitamin D has been shown to be associated with nonskeletal conditions ([@B7], [@B8]). Several recent studies have shown the possible effect of vitamin D supplementation in reducing the risk of fetal complications in pregnancies where the mother has vitamin D deficiency ([@B9]--[@B11]). These studies revealed that vitamin D deficiency is common in pregnancy and significantly increases the risk for preeclampsia, cesarean section, and GDM in later pregnancy ([@B9]--[@B13]).

Recent evidence suggests that vitamin D receptors are expressed in many different cells, including those that influence the regulation of glucose metabolism such as muscle and pancreatic beta cells ([@B14]). Vitamin D has a direct effect on pancreatic beta cells and is a prerequisite for the normal insulin secretion function of the endocrine pancreas ([@B15], [@B16]). Therefore, vitamin D deficiency is related to blood glucose and insulin concentration alterations as well as target tissue sensitivity to insulin ([@B6]). Vitamin D replenishment restores insulin secretion and sensitivity in patients with type 2 diabetes and established vitamin D deficiency ([@B17]). Therefore, it was hypothesized that GDM might result from pregnancy-induced insulin resistance and the resulting impaired insulin secretion.

The association of vitamin D with the risk of gestational diabetes has long been of interest to researchers, and many studies in a broad variety of populations have been conducted on this topic, yielding different outcomes. Some studies have showed a meaningful relationship between vitamin D status and risk of gestational diabetes whereas others have reported controversial data. With this large body of literature, an overall estimation of its association is important, as is indicated by the breadth and quality of these studies. Recently, several meta-analyses have explored the existing data on the association of serum vitamin D levels with the risk of GDM and have reported that such association indeed exists ([@B18]--[@B21]). Despite these findings, there is also data to the contrary and our knowledge about the clinical importance and implications of this association is still limited. Further studies have been published since the initial appearance of these meta-analyses, but they have not yet been effectively summarized. To authenticate these studies and as a way of synthesizing their findings, this updated meta-analysis was performed to quantitatively evaluate the association of vitamin D status (deficient vs. normal) with the risk of gestational diabetes.

Materials and Methods {#S2}
=====================

Search Strategy {#S2-1}
---------------

This meta-analysis was done on the basis of the PRISAMA statement about meta-analyses (check list S1) ([@B22]). Two researchers performed formal, independent computer searches for related published articles (to February 2017) with existent documents in the Scopus databases, Information Sciences Institute website, PubMed, EmBase, and the Cochrane Library. Keywords searched included vitamin D, 25-hydroxy vitamin D, 1,25-dihydroxycholeclciferol, and 25(OH)D with GDM. The meta-analysis was limited to studies published in English. The search scope was developed using the symbol "\*" and an advanced search of words or statements created by Boolean operators was performed. The list of recognized articles was scanned, and the reference lists of all related reviews and main articles were searched manually for more references. To decrease bias, two authors performed the searches independently, and any disagreement between them was debated in a group discussion until a consensus was achieved.

Inclusion and Exclusion Criteria {#S2-2}
--------------------------------

For further review, abstracts and titles were screened by two reviewers. Since every screened study was included in this meta-analysis, the researchers attempted to evaluate the relationship between vitamin D and the risk of GDM; determine whether it is accomplished among pregnant women without illness or as a chronic complication; use blood samples for lab tests; compare women with gestational diabetes and women with a normal glucose tolerance (NGT); report an estimation of effect \[ratios risk (RR), hazard risk (HR), or odds ratio (OR) and related confidence interval (CI) of 95%\] to compare adequate and inadequate vitamin D values. Some studies were out of the realm of the current study, which focused on pregnant women with chronic illness, and thus were excluded. Studies on non-human creatures (i.e., animal studies), those published in languages other than English, those that were meta-analyses or systematic considerations, and those that presented insufficient data or were duplicate publications were also excluded.

Data Extraction {#S2-3}
---------------

Data and information on the basis of a standard protocol were excluded after the determination was made for eligible articles. The data collected included the name of first writer, publication year, sample size, age group, present situation, study design, evaluation of the vitamin D status, and the effect estimation with a CI of 95%. In cases which needed more information, the articles' writers were contacted for supplementary data or further elucidation. Information from articles by two specialists who worked independently was considered, and their findings and results were compared later. Disagreements about study eligibility were resolved by group discussion. The information and data were entered in a standard data extraction form and finally into Microsoft Excel.

Data Synthesis and Analysis {#S2-4}
---------------------------

Reported effect estimation (OR and RR) with a CI of 95% was used as the measuring standard of the relation between vitamin D and the risk of gestational diabetes. The possible estimation of risk was maximized to evaluate the variance between some methods and levels which control studies of potential confounding factors. Statistical heterogeneity was evaluated in studies using *Q* and *I*^2^ Cochran statistics. Wherever the results of studies were heterogeneous, a random effects model was used in the meta-analysis. Subgroup analyses were carried out in search of possible heterogeneous causes. Integrated estimations and the related CI of 95%were evaluated using forest plots as visuals. Bias or publication bias was evaluated as quality using funnel plots, Egger regressions, and the Begg--Mazumdar correlation test.

Values of *p* \< 0/05 were considered as valid for heterogeneity tests. For statistical analyses, software R (version 3.2.1) and STATA (version 11.1) software were used. All statistical tests were two sided.

Results {#S3}
=======

Selected Articles {#S3-1}
-----------------

In the initial electronic search, 268 potential articles were identified; a manual search of the bibliographies and reference lists of these articles identified 12 additional articles. Altogether, 280 articles were identified through the literature search. After the initial screening of abstracts and titles, 217 articles were excluded based on the inclusion criteria (49 articles based on unrelated titles and 168 based on unrelated abstracts) and 63 articles remained for full text review. In a secondary screening and after a full-text review, another 37 articles were excluded; 4 studies were not in a population of pregnant women, 8 studies were in pregnant women with chronic diseases or conditions, 6 studies did not obtain blood samples for testing, 3 studies reported on biological mechanisms of vitamin D metabolites, 7 studies had no outcome data, and 6 studies collected insufficient data. Two studies were non-human (animal) studies, and one was not published in English. Twenty-six studies were selected for the final analysis after these exclusions (Figure [1](#F1){ref-type="fig"}).

![Flowchart of the literature search.](fendo-09-00007-g001){#F1}

Description of the Studies {#S3-2}
--------------------------

The studies used in this meta-analysis were published between 2008 and 2016 and consisted of eight cross-sectional studies ([@B7], [@B15], [@B25], [@B30], [@B31], [@B43], [@B45], [@B46]), six prospective, nested case--control studies ([@B28], [@B33], [@B35]--[@B37], [@B44]), seven retrospective case--control studies ([@B6], [@B17], [@B23], [@B24], [@B27], [@B29], [@B40]), and five prospective cohort studies ([@B16], [@B26], [@B32], [@B38], [@B47]). All 26 articles presented their findings as proportions (Table [1](#T1){ref-type="table"}).

###### 

Characteristics and information of studies evaluated in this meta-analysis.

  Reference   Country     Study design           Sample size (*n*)   Age at baseline (year)   Current status   Assay method for vitamin D[^a^](#tfn1){ref-type="table-fn"}   Mean 25(OH)D nmol/L (SD)      Significant                     
  ----------- ----------- ---------------------- ------------------- ------------------------ ---------------- ------------------------------------------------------------- ----------------------------- --------------- --------------- -----
  ([@B43])    Australia   Cross-sectional        81                  226                      32.6             Second or Third trimester                                     LC--MS                        48.6 (24.9)     55.3 (23.3)     No
  ([@B44])    US          Nested Case--control   57                  114                      33.5             24--28 weeks                                                  ELISA                         60.4 (21.22)    75.13 (24.21)   Yes
  ([@B15])    Iran        Cross-sectional        52                  579                      25.6             24--28 weeks                                                  RIA                           16.49 (10.44)   22.97 (18.25)   No
  ([@B45])    India       Cross-sectional        39                  520                      23.7             \<32 weeks                                                    RIA                           49.3 (31.2)     46.4 (30.9)     No
  ([@B23])    Iran        Case--control          54                  111                      27.4             24--28 weeks                                                  ELISA                         24.01 (20.62)   32.2 (35.74)    No
  ([@B29])    UK          Case--control          90                  158                      33.5             First trimester                                               LC--MS                        47.2 (26.7)     47.6 (26.7)     No
  ([@B24])    UK          Case--control          100                 1,000                    31.7             11--19 weeks                                                  LC--MS                        NR              NR              No
  ([@B35])    US          Nested-case--control   60                  120                      33.7             24--28 weeks                                                  LC--MS                        97.0 (29.0)     86.0 (22.0)     No
  ([@B36])    Canada      Nested-case--control   116                 218                      34.3             15--18 weeks                                                  CLIA                          56.3 (19.4)     62 (21.6)       No
  ([@B37])    China       Nested-case--control   200                 200                      32               26--28 weeks                                                  ELISA                         22.4 (10.7)     25.9 (12.3)     Yes
  ([@B46])    Spain       Cross-sectional        36                  466                      NR               11--14 weeks                                                  ECLIA                         NR              NR              NR
  ([@B30])    Spain       Cross-sectional        49                  266                      NR               24--28 weeks                                                  CLIA                          NR              NR              No
  ([@B31])    US          Cross-sectional        68                  1,264                    32               26--28 weeks                                                  CLIA                          NR              NR              No
  ([@B25])    Turkey      Cross-sectional        234                 168                      30.8             24--28 weeks                                                  ECLIA                         30.8 (16.3)     36.0 (16.2)     Yes
  ([@B26])    Qatari      Cohort                 260                 1,613                                     \>24 weeks                                                    RIA                           44.19 (20.01)   NR              Yes
  ([@B27])    Turkey      Case-control           44                  78                       26.4             24--32 weeks                                                  CLIA                          48.67 (23.21)   57.16 (24.96)   Yes
  ([@B28])    Australia   Nested case--control   376                 3,714                    33.2             First trimester                                               AIAS                          56.9 (26.9)     52.1 (22.1)     No
  ([@B7])     Canada      Cross-sectional        54                  601                      28.4             6--13 weeks                                                   LC--MS                        57.5 (17.2)     63.5 (18.9)     No
  ([@B32])    Korea       Cohort                 23                  500                      33.7             24--28 weeks                                                  ECLIA                         49.4 (19.4)     48 (24.8)       No
  ([@B38])    China       Cohort                 2,960               100                      29.7             16--20 weeks                                                  ECLIA                         NR              NR              No
  ([@B47])    Spain       Cohort                 93                  2,289                    32               13.5 weeks                                                    HPLC                          28.42 (4.39)    28.41 (0.96)    No
  ([@B16])    Canada      Cohort                 142                 125                      34.4             NR                                                            ECLIA                         NR              NR              No
  ([@B33])    US          Nested-case--control   135                 517                      33.5             18--22 weeks                                                  LC--MS                        59.7 (23.5)     66.6 (22)       No
  ([@B40])    Czech       Case--control          47                  29                       33               24--30 weeks                                                  EIASA                         28.5 (13)       31.7 (16)       No
  ([@B6])     Iran        Case--control          43                  44                       31.28            First trimester                                               Liebermann--Burchard method   33.54 (18.88)   43.23 (37.02)   Yes
  ([@B17])    India       Case--control          51                  19                       26.5             \<28 weeks                                                    RIA                           24.7 (17.6)     45.8 (28)       Yes

*Significant: significant difference in serum 25(OH)D between NGT and GDM*.

*^a^Assay method of 25(OH)D*.

*NR, not reported; LC--MS, liquid chromatography-tandem mass spectrometry; ELISA, enzyme-linked immunosorbent assay; RIA, radioimmunoassay; CLIA, chemiluminescence immunoassay; ECLIA, ElectroChemiLuminescence immunoassay; AIAS, automated immunoassay system; HPLC, high-performance liquid chromatography*.

Main Analysis {#S3-3}
-------------

Studies reporting OR were collected to determine the association between vitamin D deficiency and gestational diabetes. Seven studies showed a meaningful relationship between vitamin D status and risk of gestational diabetes, and 19 other cases showed no significant relationship. Thus, the present meta-analysis used a random effects model to show that vitamin D deficiency is related to an increased risk of GDM (OR = 1.18; 95% CI, 1.01--1.35; *p* \< 0.001) (Figure [2](#F2){ref-type="fig"}). The reviewed studies showed limited evidence of heterogeneity (*I*^2^ = 8.1%; *p* = 0.346).

![Relationship between insufficient vitamin D and risk of GDM.](fendo-09-00007-g002){#F2}

Sensitivity and Subgroup Analyses {#S3-4}
---------------------------------

Eighteen studies from 26 cases provided their findings as averages and means; 12 of these 18 studies reported a relationship between vitamin D deficiency and GDM. The current meta-analysis was performed to determine whether there is a meaningful difference between the average vitamin D levels in women with and those without gestational diabetes. According to the random effects model, the average standard equation difference was −2.26 (SMD) (CI at 95% = −0.39 to −0.14), which indicates that heterogeneity was significant (*I*^2^ = 68.8%, *p* \< 0.001) (Figure [3](#F3){ref-type="fig"}).

![Relationship between serum 25(OH)D level and GDM.](fendo-09-00007-g003){#F3}

These results showed that pregnant women with GDM have lower vitamin D values than the compared group.

A sensitive analysis was also performed in the current research. After each study was sequentially removed from the analysis, the relative risk of the overall composition did not change. Thus, it was concluded that no special study would affect the results.

A subgroup analysis of gestational diabetes was conducted in the current study to minimize heterogeneity among various studies. As can be seen in Figure [4](#F4){ref-type="fig"}, a study showed that vitamin D deficiency is correlated with an increased risk of gestational diabetes if the study did not use a cross-sectional and cohort design (Figure [4](#F4){ref-type="fig"}).

![Relationship between serum 25(OH)D level and GDM based on study design.](fendo-09-00007-g004){#F4}

This relationship was also considered on the basis of region. Of the 26 studies, 2 were conducted in Australia ([@B28], [@B43]), 7 in North America ([@B7], [@B16], [@B31], [@B33], [@B35], [@B36], [@B44]), 9 in Asia ([@B6], [@B15], [@B17], [@B23], [@B26], [@B32], [@B37], [@B38], [@B45]), and 8 in Europe ([@B24], [@B25], [@B27], [@B29], [@B30], [@B40], [@B46], [@B47]). The results of the current meta-analysis showed that there is no significant relationship between the status of vitamin D and the risk of gestational diabetes based on geographical area (Figure [5](#F5){ref-type="fig"}).

![Relationship between serum 25(OH)D level and GDM based on region.](fendo-09-00007-g005){#F5}

Publication Bias {#S3-5}
----------------

The funnel plots presented in the Begg--Mazumdar test showed no signs of publication bias in the studies considered. Figure [6](#F6){ref-type="fig"} shows the shape of funnel plots of tests related to vitamin D deficiency in patients with GDM. Egger and Begg tests showed no evidence of publication bias (*p* = 0.864 for Egger; *p* = 0.553 for Begg's; Figure [7](#F7){ref-type="fig"}).

![Funnel plot (from Begg--Mazumdar test) for publication bias.](fendo-09-00007-g006){#F6}

![Begg--Mazumdar rank correlation and Egger regression tests for publication bias. OR, odds ratio.](fendo-09-00007-g007){#F7}

Discussion {#S4}
==========

The current systematic study and quantitative meta-analysis found a relationship between the rate of vitamin D deficiency and gestational diabetes from 26 observational studies. The current results were consistent with those of previous meta-analyses. A 2012 meta-analysis reported from 7 observational studies that vitamin D deficiency in relation with GDM is meaningful and significant; it should be added, however, that according to an entrance study, this relationship remains unclear ([@B18]). A 2013 meta-analysis from 10 observational studies showed that there is a significant association between vitamin D deficiency and undesirable results in gestation and birth variables ([@B19]). In a 2015 meta-analysis from 20 observational studies, the relationship between vitamin D deficiency and an increased risk of GDM was confirmed ([@B20]). A 2016 subsequent meta-analysis reported a meaningful reverse relationship between the level of vitamin D and the risk of gestational diabetes ([@B21]).

We observed that vitamin D deficiency had a positive association with GDM in 7 of 26 studies and 19 of 26 studies did not support this conclusion; however, our results showed a mild positive association between vitamin D status with GDM. In previous meta-analyses also have such a case ([@B19]--[@B21]). It should be mentioned that in meta-analysis sample size and SD are very important in combining the results of studies, in extreme situation maybe more studies do not show significance association but few studies with big sample size show big effect size and significance results. This matter affected our and previous meta-analyses.

As previously mentioned, there have been further developments in the subject literature since the publication of these meta-analyses, and the previous meta-analyses did not include several important observational studies; the current meta-analysis is an attempt to fill this gap. The previous meta-analysis showed that vitamin D insufficiency was associated with increased gestational diabetes risk by 45% ([@B21]), but we added some studies to previous meta-analysis and concluded that vitamin D insufficiency increased the risk of gestational diabetes by 18%. The current findings suggest softening the conclusion in previous meta-analysis and show that vitamin D deficiency may increase the risk of gestational diabetes.

In the present study, we found that the serum level of 25(OH)D was significantly lower in women with gestational diabetes than in women with NGT. Most of the reviewed studies reported that pregnant women with GDM have lower vitamin D values than the compared group ([@B7], [@B15], [@B17], [@B25], [@B33], [@B36], [@B37], [@B40], [@B43], [@B44]). The previous meta-analyses also evaluated weighted mean differences between the average vitamin D levels in women with and those without gestational diabetes and their results were consistent with ours ([@B18], [@B20]). According to these findings, it can be said that low levels of 25(OH)D may be considered a risk factor during gestation.

It is important to note that the relationship between the mother's vitamin D status and the risk of gestational diabetes can be affected by various factors. Some possible contributing factors are mother's age and body mass index (BMI). Different studies have shown a correlation between gestational diabetes and a mother's high age, high BMI, and reduced physical activity ([@B41], [@B48]). Obesity and high age in the mother are independent risk factors for both vitamin D deficiency and gestational diabetes; consequently, they can be considered as means of the relationship between vitamin D deficiency and gestational diabetes ([@B18]). More entrance studies in the current meta-analysis were regulated on the basis of mother's age and BMI. However, the relationship of vitamin D status and gestational diabetes was statistically significant.

The consumption of pre-natal multivitamins or nutritional supplements is one of the factors that can affect the relationship between maternal vitamin D status and the risk of developing gestational diabetes. A systematic study and meta-analysis showed that daily vitamin D supplementation (800--1,000 IU per day) has protective effects on maternal health outcomes before and after childbirth and/or on the newborn ([@B42]). The researchers also showed that vitamin D supplementation during the gestational period has a positive effect on glycemic, sensitivity, and insulin resistance as well as metabolic characteristics ([@B34], [@B39], [@B49]).

Other contributing factors or possibly risky factors may be exposure to sunlight, which has an intensive relationship with geographical situation, season, and weather; skin color and the use of sunscreen; and even air pollution ([@B50]). Recent evidence has shown that inadequate vitamin D levels are completely common in pregnant women who have limited exposure to sunlight. Some of the sample people who may be less exposed to sunlight are people who live in a geographical area with cold weather, those who wear clothes that are protective against sunlight, and/or those who are from ethnic groups of darker-colored skin ([@B51]--[@B53]). First, vitamin D is produced in skin which is exposed to ultraviolet B rays that stimulate the production of serum levels of 25(OH)D depending on the season; higher levels are seen in spring and summer ([@B18]).

Other factors can also be related to the risk of gestational diabetes, including smoking, alcohol consumption, weight gain associated with pregnancy, and social and economic status. The contribution of these confounding factors to the risk of GDM can go some distance in explaining the conflicting results among different studies.

In the current study, subgroup analysis based on the research project of various studies in the meta-analysis showed that inadequate vitamin D is correlated with an increased risk of gestational diabetes if the studies did not use a cross sectional and cohort design. Since many of the studies reviewed in the present work had a case--control design, this may have led to overestimation of the effect size of the association. Similarly, previous meta-analyses confirmed the current results in this regard, showing that study design can be one explanation for heterogeneity among studies included in a meta-analysis ([@B19]--[@B21]).

Another significant point is that entrance studies had used different methods and standards to recognize gestational diabetes. On the other hand, serum level 25(OH)D was measured in different quarterly courses, the definitions of deficiency or inefficiency of 25(OH)D were different, and different techniques were used. Some studies suggest that the method used to quantify 25(OH)D levels and the diagnosis of gestational diabetes could be an important factor and influence the final results ([@B54], [@B55]).

The possible mechanisms related to the relationship between vitamin D and gestational diabetes are as follows: (1) The direct effect of vitamin D on the performance of β cells of the pancreas has a regulating effect on the rate of circulating glucose in the blood which is transmitted through the connection of 1,25(OH)~2~D~3~ to vitamin D receiver of β cells of the pancreas. Glucose stimulates the expression of insulin receptors and the 25-hydroxyvitamin D-1-α-hydroxylase enzyme and increases the insulin response for transfusion ([@B56]--[@B58]). (2) The effect on intracellular calcium regulation, which plays a major and important role in insulin-mediated intracellular processes of insulin-receptor tissue ([@B59]). (3) Effects on systemic inflammation along with insulin resistance in patients with diabetes mellitus ([@B60]).

Limitation {#S4-1}
----------

This meta-analysis had several limitations. First, there were some differences among studies regarding the definition of the limits for vitamin D deficiency and the criteria for a diagnosis of GDM, which may be affected by accumulation. Second, the impact of some of the most important factors that may affect the relationship between vitamin D deficiency and gestational diabetes, including weight gain in pregnancy, skin color, and socioeconomic status, could not be evaluated due to inadequate data and information in some studies. Data on exposure to sunlight and vitamin D intake were not available. Third, the most adjusted OR was used in this meta-analysis. However, modulated models varied in different studies. Also, in some studies, the potential confounding factors could not be adjusted; so, the findings cannot be collected by adjusting the confounding factors. In addition, in meta-analysis sample size and SD are very important in combining the results of studies; this subject affected our study. Furthermore, the possible effects of publication bias inherent in any meta-analysis cannot be ruled out.

Conclusion {#S5}
==========

The present meta-analysis shows that women with GDM had significantly less serum vitamin D than women who have NGT. The current finding shows that low levels of 25(OH)D may be considered a risk factor during gestation. Also, the results showed that there is a mild positive association between maternal vitamin D deficiency and GDM and suggested softening the reported conclusion in previous meta-analysis. In conclusion, our results show that vitamin D deficiency may increase the risk of gestational diabetes. Based on different research projects and the heterogeneity among various studies, it is not logical to make a definitive conclusion. More clinical trials and studies are needed to determine the effects of vitamin D supplements on the prevention of gestational diabetes. Based on these findings, healthcare providers should encourage pregnant women to follow the guidelines for the daily intake of vitamin D.

Ethics Statement {#S6}
================

This study has a code of ethics by the Ethics Committee of Ilam University of Medical Sciences (ir.medilam.rec.1395.102).

Author Contributions {#S7}
====================

MA and SM designed the study and participated in data collection; KS, AM, and ES performed the meta-analysis; AM, SFM, ES, and SM participated in drafting the paper; KS and ES critically revised the paper; all authors provided data analysis, read, and approved the manuscript.

Conflict of Interest Statement {#S8}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors would like to express their gratitude for the support of the Deputy of Research and Technology, Ilam University of Medical Sciences.

[^1]: Edited by: Anne E. Sumner, National Institutes of Health (NIH), United States

[^2]: Reviewed by: Dubravka Jurišić Eržen, University of Rijeka, Croatia; Menachem M. Meller, Mercy Philadelphia Hospital, United States

[^3]: ^†^Joint first authors.

[^4]: Specialty section: This article was submitted to Diabetes, a section of the journal Frontiers in Endocrinology
